The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target

• Published in: British journal of anaesthesia : BJA Vol. 122; no. 6; pp. e157 - e167
• Main Authors: Chen, D.T., Pan, J.H., Chen, Y.H., Xing, W., Yan, Y., Yuan, Y.F., Zeng, W.A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2019
• Subjects: cancer; cancer therapy; carcinoma; hepatocellular; metastasis; mu opioid receptors; opioids; prognosis; cancer therapy; carcinoma; metastasis; cancer; prognosis; mu opioid receptors; hepatocellular; opioids

Opioid receptors are implicated in cancer progression and long-term patient outcomes. However, the prognostic significance, underlying mechanisms, and therapeutic value of mu-opioid receptor (MOP) in hepatocellular carcinoma (HCC) remain unclear. MOP expression in human biopsy HCC samples was evalua...